Other Events ·
HUTCHMED announced an exclusive development and license agreement with GSK for HMPL-A830, a first-in-class KRAS-EGFR…
HCMHUTCHMED (China) Ltd
HUTCHMED announced an exclusive development and license agreement with GSK for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate. HUTCHMED receives a US$110 million upfront payment and potential milestone payments up to US$1.295 billion, plus tiered royalties on net sales. GSK holds worldwide rights excluding Mainland China, Hong Kong, Macau, and Taiwan. Clinical development for colorectal, pancreatic, and lung cancer is expected to begin in H2 2026. HUTCHMED operates as a biopharmaceutical company focused on targeted therapies and immunotherapies for cancer.